New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 3, 2014
15:40 EDTAKBANovo A/S reports 7.5% stake in Akebia
News For AKBA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 9, 2015
18:03 EDTAKBAAkebia management to meet with Needham
Meeting to be held in the Midwest on October 13 hosted by Needham.
October 6, 2015
14:18 EDTAKBAAkebia new clarity on trials debunks bear case, says Brean Capital
Brean Capital said Akebia's agreement with the FDA and EMA on a Phase 3 program in ND-CKD for vadadustat. Analyst Jonathan Aschoff said the new clarity for the trials debunks the bear case that the FDA would not allow Akebia to conduct Phase 3s due to CV safety concerns from prior Phase 2 results. Aschoff also believes that Akebia prefers to have a Japanese partner around year end 2015, prior to initiation, and that it could also begin enrollment itself if talks with a front-running potential Japanese partner are well advanced. Aschoff rates shares a Buy with a $26 price target.
08:04 EDTAKBAAkebia reaches agreement with FDA, EMA on Vadadustat Phase 3 program
Subscribe for More Information
September 29, 2015
07:27 EDTAKBAAkebia management struck confident tone on partnering, says Brean Capital
After hosting management meetings with Akebia Therapeutics, Brean Capital analyst Jonathan Aschoff noted that management's tone regarding the likelihood of partnering vadadustat in Japan and the EU would best be described as "highly confident." The analyst has a Buy rating and $26 price target on Akebia shares.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use